Li Fei, Qi Bing, Yang Le, Wang Bao, Gao Li, Zhao Minggao, Luo Lanxin
Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China; Department of Pharmacy, The Hospital of 92880 Troops, PLA Navy, Zhoushan, Zhejiang 316000, China.
Central Laboratory, The Second Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi 710038, China.
Clin Immunol. 2022 Dec;245:109158. doi: 10.1016/j.clim.2022.109158. Epub 2022 Oct 14.
Effective immunotherapies for patients with glioblastoma (GBM) are urgently needed. Chitinase-3 like-protein-1 (CHI3L1) play important roles in the development of gliomas. However, its role in glioma-related immune responses remains unclear. We aimed to comprehensively investigate its biological features and clinical value in glioma, especially in GBM. Transcriptome, proteome and single-cell RNA-sequencing databases were enrolled in the study. Immunostaining and immunoblotting were performed for validation. CHI3L1 was highly correlated with clinical and molecular features, suggesting that high CHI3L1 expression is more likely to be predicted as malignant entities. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed CHI3L1 closely associated with immune responses and inflammatory activities in GBM. In addition, CHI3L1 also correlated with immune cell infiltration and immune checkpoints. Our study suggests that inhibition of CHI3L1 may help to reduce immunosuppression and overcome immunotherapy resistance, which would be an therapeutic area for the treatment of GBM.
胶质母细胞瘤（GBM）患者急需有效的免疫疗法。几丁质酶-3样蛋白-1（CHI3L1）在胶质瘤的发展中起重要作用。然而，其在胶质瘤相关免疫反应中的作用仍不清楚。我们旨在全面研究其在胶质瘤，尤其是GBM中的生物学特征和临床价值。本研究纳入了转录组、蛋白质组和单细胞RNA测序数据库。进行免疫染色和免疫印迹以进行验证。CHI3L1与临床和分子特征高度相关，这表明CHI3L1高表达更有可能被预测为恶性实体。基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析表明，CHI3L1与GBM中的免疫反应和炎症活动密切相关。此外，CHI3L1还与免疫细胞浸润和免疫检查点相关。我们的研究表明，抑制CHI3L1可能有助于减轻免疫抑制并克服免疫治疗耐药性，这将是GBM治疗的一个治疗领域。
